Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye

Peters, Swaantje; Heiduschka, Peter; Julien, Sylvie; Bartz-Schmidt, Karl-Ulrich; Schraermeyer, Ulrich

doi:10.1136/bjo.2007.133496

Cited by 18 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an animal study, bevacizumab penetrated quickly into the iris, anterior chamber angle and ciliary body after IVB. This finding supports the clinically observed rapid effect of bevacizumab in the treatment of iris neovascularization [64]. This injection may provide us with sufficient time to treat these patients with retinal photocoagulation.…”

Section: Neovascular Glaucomasupporting

confidence: 85%

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

Kimoto

Kubota

2012

Journal of Ophthalmology

View full text Add to dashboard Cite

We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-VEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an effective treatment for macular edema after retinal vein occlusion, however, recurrent/persistent edema is common. The recent reports may lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs. There have been several well-publicized prospective, randomized studies that demonstrated the efficacy of intravitreal injection of anti-VEGF drugs for patients with AMD. Adjuvant bevacizumab for neovascular glaucoma may prevent further PAS formation, and it is likely to open up a therapeutic window for a panretinal photocoagulation and trabeculectomy. Intravitreal injection of bevacizumab (IVB) results in a substantial decrease in bleeding from the retinal vessels or new vessels during a standard vitrectomy. IVB has also been reported to be effective for inducing the regression of new vessels in proliferative diabetic retinopathy. The use of bevacizumab in stage 4 or 5 retinopahty of permaturity (ROP) is to reduce the plus sign to help reduce hemorrhage during the subsequent vitrectomy. Some authors reported cases of resolution of stage 4 A ROP after bevacizumab injection.

show abstract

Section: Neovascular Glaucomasupporting

confidence: 85%

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

Kimoto

Kubota

2012

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

“…19,29,33 In animal studies, the immunoreactivity of bevacizumab was detected in blood vessel walls of the iris, anterior chamber angle, ciliary body, choroid, and the inner layers of the retina, especially in the ganglion cell layer and inner nuclear layer. 19,29,33 The VEGF immunoreactivity was found to be nondetectable for the next 14 days after bevacizumab injection. 29 In the studies reported by Heiduschka et al 19 and Shahar et al, 34 immunoreactivity of bevacizumab could not be detected 25 days and 30 days after intravitreal injection, respectively.…”

Section: Discussionmentioning

confidence: 98%

Effects of Intravitreal Bevacizumab in Repeated Doses

Sari¹,

Adigüzel²,

Canacankatan³

et al. 2009

Retina

View full text Add to dashboard Cite

A repeated dose of intravitreal bevacizumab injection did not cause a toxic effect on cornea and uveoretinal tissue. Biochemically, it also did not cause any apoptosis, oxidative reaction, or lipid peroxidation. Instead, bevacizumab injection caused a considerable decrease in the apoptotic enzyme activities and lipid peroxidation in the uveoretinal tissue. Further studies are needed to be conducted for possible detrimental side effects and apoptotic and oxidative effects of repeated bevacizumab injections on both the injected and the contralateral eyes.

show abstract

“…This may allow intravitreal BV to diffuse toward and reach the VR junction sooner, and it may also enable the molecule to leave the intraocular cavity via alternative exit routes. Intravitreal BV has been shown to penetrate into the iris, ciliary body, and anterior chamber angle shortly after injection, and its distribution in the anterior chamber angle is time-dependent 30. Two exit pathways have been described to explain the distribution and the decline in ranibizumab levels in the vitreous cavity and aqueous humor 31.…”

Section: Discussionmentioning

confidence: 99%

Posterior Vitreous Detachment With Microplasmin Alters the Retinal Penetration of Intravitreal Bevacizumab (Avastin) in Rabbit Eyes

Goldenberg¹,

Giblin²,

Cheng³

et al. 2011

Retina

View full text Add to dashboard Cite

Purpose-Intravitreal bevacizumab (Avastin) is frequently used for the treatment of age-related macular degeneration. Previous studies have demonstrated full thickness retinal penetration. Intravitreal recombinant microplasmin (MP) has been shown to successfully induce a posterior vitreous detachment (PVD) and vitreous liquefaction in animals. It has been suggested that a PVD may alter the retinal penetration of molecules in the vitreous cavity. The aim of this study was to compare bevacizumab (BV) retinal penetration in rabbit eyes with and without a MP-induced PVD.Methods-Twelve adult rabbits were injected with 0.1 ml (0.4 mg) of MP into the vitreous cavity of one eye. One week later, the rabbits were injected with 0.05 ml (1.25 mg) of BV into both eyes. Both eyes of three rabbits each were harvested at 6, 12, 24, and 72 hours after the BV injection. Frozen retinal cross sections were prepared, and BV retinal penetration was evaluated with immunohistochemistry using a fluorescence-labeled antibody against BV. Two eyes from one rabbit were not injected with either agent and used as controls to compare the background autofluorescence. Peripapillary retinal sections were recorded with a digital camera, and intraretinal BV fluorescence-labeled antibody was measured by qualitative photographic interpretation. Two additional rabbits received an intravitreal injection of 0.1 ml of MP in one eye. One week later, both eyes from each rabbit were enucleated and frozen retinal sections were prepared and analyzed with light microscopy to evaluate for histologic damage.Results-Full thickness BV retinal penetration was observed throughout the retina in both eyes of each rabbit. All of the MP-injected eyes exhibited increased antibody labeling in retinas evaluated 6, 12, and 24 hours after BV injection when compared with the contralateral non-MPinjected eyes. By three days after BV injection, all eyes demonstrated decreased antibody labeling compared to earlier time periods. At three days, one rabbit showed increased antibody labeling in the retina of the non-MP-injected eye compared with the contralateral MP-injected eye, and two Presented in part at the annual meetings of the Association for Research in Vision and Ophthalmology, May, 2008 (Fort Lauderdale, Florida) and the American Society of Retinal Specialists, October 2008 (Maui, Hawaii) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author ManuscriptRetina. Author manuscript; available in PMC 2012 February 1. 18 showed that a MP-induced PVD increases vitreous oxygen levels and increases the rate of oxygen exchange within ...

show abstract

Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye

Cited by 18 publications

References 12 publications

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

Effects of Intravitreal Bevacizumab in Repeated Doses

Posterior Vitreous Detachment With Microplasmin Alters the Retinal Penetration of Intravitreal Bevacizumab (Avastin) in Rabbit Eyes

Contact Info

Product

Resources

About